Oxaliplatin plus irinotecan seems highly promising as a first-line treatment option

Author:  

Publisher: Adis International

ISSN: 1173-8324

Source: Inpharma, Vol.1, Iss.1327, 2002-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract